What Burden of Prostate Cancer Can Radiologists Rule Out on Multiparametric Magnetic Resonance Imaging? A Sensitivity Analysis Based on Varying the Target Condition in Template Prostate Mapping Biopsies

Anastasiadis, Eleni; Charman, Susan C.; Arumainayagam, Nimalan; Sohaib, Aslam; Allen, Clare; Freeman, Alex; Emberton, Mark; Ahmed, Hashim U.

doi:10.1016/j.urology.2015.05.010

Cited by 3 publications

(2 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Branger ve ark. 47 yaptığı çalışmada, klinik anlamlı PK tanısında tecrübeli radyologlar ile negatif prediktif değerin %95'e kadar yükseldiği belirlenmiştir. MpMRI'ın klinik pratik kullanım avantajlarının yanında mali yükü de göz önünde bulundurulmalıdır.…”

Section: Mpmri (Multiparametrik-mri)unclassified

Reflex Tests of Prostate Cancer Diagnosis

Danacıoğlu¹,

Erol²,

Çaşkurlu³

2018

MMJ

View full text Add to dashboard Cite

Section: Mpmri (Multiparametrik-mri)unclassified

Reflex Tests of Prostate Cancer Diagnosis

Danacıoğlu¹,

Erol²,

Çaşkurlu³

2018

MMJ

View full text Add to dashboard Cite

“…In a cohort of 101 patients, Branger et al showed that a negative MRI could not exclude the presence of clinically significant cancer (manifest by Gleason pattern 4 or extraprostatic extension) (38). However, experienced radiologists can exclude significant volumes (core length ≥5 mm) of Gleason score ≥7 prostate cancer with a negative predictive value exceeding 95% (39). …”

Section: Magnetic Resonance Imaging (Mri) Of the Prostatementioning

confidence: 99%

Role of mpMRI of the prostate in screening for prostate cancer

Wallis

Haider

Nam

2017

Transl. Androl. Urol.

View full text Add to dashboard Cite

Prostate cancer screening offers the opportunity to significantly reduce morbidity and mortality from this disease. Currently, serum prostate-specific antigen (PSA) testing is the most widely used screening modality. However, PSA testing continues to have low positive and negative predictive value leading to unnecessary invasive prostate biopsy while missing patients with aggressive forms of the disease. Magnetic resonance imaging (MRI) has been gaining an increasingly large role in the management of patients with early stage prostate cancer including diagnosis in patients with abnormal PSA levels, monitoring of patients on active surveillance, and staging prior to definitive interventions. MRI-based prostate cancer risk assessment has been shown to better distinguish between clinically-significant and insignificant tumors than PSA testing alone or from nomograms. Preliminary data indicate that, among unselected patients, MRI outperforms PSA in the identification of patients with clinically significant prostate cancer. Further work is needed to examine the role of mpMRI in prostate cancer screening.

show abstract

Prostate Cancer Screening Recommendations for General and Specific Populations in the Western Nations

King

Nittala

Gordy

et al. 2020

EMJ

View full text Add to dashboard Cite

There is a chaotic scenario that exists in the field of prostate cancer (PCa) screening. To balance goals, such as decreasing mortality, avoiding unnecessary procedures, and decreasing the cost of medical care, the pendulum seems to have swung to the side of more restricted screening. The decrease in PCa screening has led to a slowly creeping decline in the favourable outcomes that existed among patients with PCa. If a potential patient or a family member is trying to get clear guidance about PCa screening by searching the internet, they will end up confused by several recommendations from many organisations. It is even more challenging to obtain any clarity about PCa screening for special populations, such as those with a family history of PCa, those of African descent/African Americans, and the elderly. The advent of genomic medicine and precision medicine is an opportunity to identify those at a very high risk of developing aggressive PCa, so that PCa screening can be more actively undertaken among them. In this paper, the authors review the current recommendations by different entities and summarise emerging molecular markers that may help bring clarity to PCa screening. The authors predict that concrete, consensual guidelines will emerge in less than one decade. Meanwhile, this article suggests intermediary steps that will help save lives from PCa mortality, especially for under-represented populations. This paper is a catalyst to stimulate further discussion and serves as a guide to noncancer-specialists for the near future as precision medicine progresses to better understand risk–benefit and cost–benefit ratios in PCa screening.

show abstract

What Burden of Prostate Cancer Can Radiologists Rule Out on Multiparametric Magnetic Resonance Imaging? A Sensitivity Analysis Based on Varying the Target Condition in Template Prostate Mapping Biopsies

Cited by 3 publications

References 33 publications

Reflex Tests of Prostate Cancer Diagnosis

Reflex Tests of Prostate Cancer Diagnosis

Role of mpMRI of the prostate in screening for prostate cancer

Prostate Cancer Screening Recommendations for General and Specific Populations in the Western Nations

Contact Info

Product

Resources

About